Literature DB >> 28325537

Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Testicular Cancer: Minimizing Surgical Morbidity.

Sumeet Syan-Bhanvadia1, Soroush T Bazargani1, Thomas G Clifford1, Jie Cai1, Gus Miranda1, Siamak Daneshmand2.   

Abstract

BACKGROUND: Retroperitoneal lymph node dissection (RPLND) is an important component of the management of testicular germ cell tumor (GCT) but carries significant surgical morbidity.
OBJECTIVE: To describe our experience with a midline extraperitoneal (EP) approach to RPLND for seminomatous and nonseminomatous GCT. DESIGN, SETTING, AND PARTICIPANTS: From 2010 to 2015, 122 consecutive patients underwent RPLND from a prospective database. Patients requiring aortic resection or retrocrural dissection or with intraperitoneal disease were excluded. The remaining 69 patients underwent midline EP-RPLND. SURGICAL PROCEDURE: Open midline EP-RPLND was performed using a standardized technique. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Perioperative and long-term outcomes were analyzed. Complications were graded using the Clavien-Dindo classification. A descriptive analysis using SAS software was performed. RESULTS AND LIMITATIONS: A total of 68 patients underwent midline EP-RPLND successfully (98.6%). The median age was 28 yr (range 17-55). On preoperative imaging the size of the retroperitoneal mass or lymphadenopathy was <2cm in 29 patients, 2-4.9cm in 15 patients, and >5cm in 24 patients, of which 19 were >10cm. The median estimated blood loss was 325ml (interquartile range [IQR] 200-612.5). The median number of lymph nodes resected was 36 (IQR 24.5-49); the median number of positive nodes was one (IQR 0-4). The median time for return of bowel function was 2 d (IQR 1-2) and hospital stay 3 d (IQR 3-4). There were no cases of ileus. Eleven patients had 12 (17.6%) 90-d complications. Of these, six (55%) were Clavien grade 1, five (45%) were grade 2, and one was grade 3b (1.5%). Antegrade ejaculation rates were 91.6% in the primary group and 96.8% in the post-chemotherapy group.
CONCLUSIONS: Midline EP-RPLND can be performed safely without compromising the completeness of the resection. This approach is associated with rapid return of bowel function, minimal rates of ileus, and short hospital stay. PATIENT
SUMMARY: A midline extraperitoneal approach for retroperitoneal lymph node dissection in testicular cancer is safe and effective and leads to faster return of bowel function and earlier discharge.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Extraperitoneal; Germ cell tumor; Nonseminomatous germ cell tumor; Retroperitoneal lymph node dissection; Testis cancer

Mesh:

Year:  2017        PMID: 28325537     DOI: 10.1016/j.eururo.2017.02.024

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  8 in total

1.  Primary robotic RLPND for nonseminomatous germ cell testicular cancer: a two-center analysis of intermediate oncologic and safety outcomes.

Authors:  Nicholas R Rocco; Sean P Stroup; Haidar M Abdul-Muhsin; Michael T Marshall; Michael G Santomauro; Matthew S Christman; James O L'Esperance; Erik P Castle
Journal:  World J Urol       Date:  2019-09-09       Impact factor: 4.226

2.  Effect of alvimopan on gastrointestinal recovery and length of hospital stay after retroperitoneal lymph node dissection for testicular cancer.

Authors:  Kushan D Radadia; Nicholas J Farber; Alexandra L Tabakin; Wei Wang; Hiren V Patel; Charles F Polotti; Robert E Weiss; Sammy E Elsamra; Isaac Y Kim; Eric A Singer; Mark N Stein; Tina M Mayer; Thomas L Jang
Journal:  J Clin Urol       Date:  2018-07-23

3.  Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility.

Authors:  Christian D Fankhauser; Luca Afferi; Sean P Stroup; Nicholas R Rocco; Kathleen Olson; Aditya Bagrodia; Fady Baky; Walter Cazzaniga; Erik Mayer; David Nicol; Ekrem Islamoglu; Stephane de Vergie; Ragheed Saoud; Scott E Eggener; Sebastiano Nazzani; Nicola Nicolai; Lee Hugar; Wade J Sexton; Deliu-Victor Matei; Ottavio De Cobelli; Joseph Cheaib; Phillip M Pierorazio; James Porter; Thomas Hermanns; Robert J Hamilton; Andreas Hiester; Peter Albers; Noel Clarke; Agostino Mattei
Journal:  World J Urol       Date:  2022-03-13       Impact factor: 4.226

Review 4.  A Review of Outcomes and Technique for the Robotic-Assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer.

Authors:  Zeyad R Schwen; Mohit Gupta; Phillip M Pierorazio
Journal:  Adv Urol       Date:  2018-05-03

Review 5.  Primary and post-chemotherapy robotic retroperitoneal lymph node dissection for testicular cancer: a review.

Authors:  Shagnik Ray; Phillip M Pierorazio; Mohamad E Allaf
Journal:  Transl Androl Urol       Date:  2020-04

Review 6.  Robot-assisted retroperitoneal lymphadenectomy: The state of art.

Authors:  Gilberto J Rodrigues; Giuliano B Guglielmetti; Marcelo Orvieto; Kulthe Ramesh Seetharam Bhat; Vipul R Patel; Rafael F Coelho
Journal:  Asian J Urol       Date:  2020-10-03

7.  Nerve-sparing Robot-assisted Retroperitoneal Lymph Node Dissection: The Monoblock Technique.

Authors:  Luca Afferi; Philipp Baumeister; Christian Fankhauser; Livio Mordasini; Marco Moschini; Fabian Aschwanden; Agostino Mattei
Journal:  Eur Urol Open Sci       Date:  2021-08-15

Review 8.  Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma.

Authors:  Brian Hu; Siamak Daneshmand
Journal:  Adv Urol       Date:  2018-02-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.